Posting of Annual Report & Accounts and AGM Notice

RNS Number : 0835L

Avacta Group PLC

07 January 2016

 

7 January 2016

Avacta Group plc

("Avacta" or the "Group")

Posting of Annual Report & Accounts and AGM Notice

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, confirms that the Annual Report and Accounts for the year ended 31 July 2015, the Notice of the Annual General Meeting and a Form of Proxy were posted to shareholders on 30 December 2015.

The Annual General Meeting is to be held on Monday 25 January 2016 at 2.00pm GMT at the offices of Walker Morris, Kings Court, 12 King Street, Leeds, LS1 2HL.

A copy of the Annual Report & Accounts and Notice of Annual General Meeting is available on the Company's website: www.avacta.com.

Enquiries:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
Numis Securities Limited     Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking	Tel:  [phone] www.numiscorp.com
Media Enquiries FTI Consulting Simon Conway/Natalie Garland-Collins	Tel: [phone] [e-mail]

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. The Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. The Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on oncology and bleeding disorders as well as several partnered development programmes. Avacta is commercialising Affimer reagents through custom Affimer services to provide bespoke solutions to customers and via a growing on-line catalogue of Affimer reagents.

 

END

 

 

ACSDBGDBUSGBGLL